CDXC Overview
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading chart...
The current price of CDXC is 0 USD — it has increased 0
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Wall Street analysts forecast CDXC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDXC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Chromadex Corp revenue for the last quarter amounts to 25.58M USD, increased 31.21
Chromadex Corp. EPS for the last quarter amounts to 0.02 USD, decreased -300.00
Chromadex Corp (CDXC) has 106 emplpoyees as of April 01 2026.
Today CDXC has the market capitalization of 0.00 USD.
